Search by Categories
- Insights
- Rare Disease
- Oncology
- Cell and Gene Therapy
- Medical Devices
- Consulting
- News & Analysis
-
Therapeutic Areas
Our expertise in the industry
Boehringer Ingelheim’s Diabetic Macular Ischemia Study; Novartis’ Mariana Oncology Acquisition; Astellas and Poseida Therapeutics Partnership; Prime Medicine’s PM359 IND; Pfizer’s TIVDAK FDA Approval
Boehringer Ingelheim Announces Promising Findings From Groundbreaking Study on Diabetic Macular Ischemia Boehringer Ingelheim released encouraging results from the HORNBILL Phase I/IIa trial of BI 764524, marking the pioneering investigation into a potential therapy for individuals with diabetic macular ischemia (DMI). The research revealed that BI 764524 was well received when administered intravitreally in both single and multiple doses, successfully achieving its main safety objectives while demonstrating initial indications of effectiveness. Diabetic macular ischemia is a frequent and permanent consequence of diabetic retinopathy with the potential to cause vision loss.…
FcRn Inhibitors for Autoimmune Disorders: A Promising Therapeutic Approach
Autoimmune disorders, a group of conditions where the immune system mistakenly attacks healthy cells, affect millions worldwide, often leading to debilitating symptoms and reduced quality of life. Traditional treatments for autoimmune disorders have primarily focused on suppressing the immune system, which can leave patients vulnerable to infections and other complications. However, recent advancements in medical research have opened up new avenues for targeted therapies, including the promising field of FcRn inhibitors. Understanding FcRn: Guardians of Immunoglobulins FcRn, or neonatal Fc receptor, plays a crucial role in the immune system by…
Insights into Cancer Cachexia Treatment: Unraveling the Mystery
Cancer cachexia, a debilitating condition characterized by severe weight loss and muscle wasting, complicates the battle against cancer. Approximately half of all patients with cancer experience cachexia. This rate of occurrence rises to as high as 86% in the last 1–2 weeks of life, with 45% of patients losing more than 10% of their original body weight over disease progression. Cancer cachexia impacts approximately 60% of the 1.4 million patients diagnosed with cancer in the United States each year. Additionally, the occurrence of cachexia varies across cancer types and ranges…